https://blackfin.bio/ 2023-12-12T08:12:00+00:00 https://blackfin.bio/wp-content/uploads/blackfin-bio-feat-1.jpg https://blackfin.bio/wp-content/uploads/arrow-dwn4.png https://blackfin.bio/wp-content/uploads/arrow-dwn4.png https://blackfin.bio/wp-content/uploads/icon.png https://blackfin.bio/wp-content/uploads/icon.png https://blackfin.bio/cookie-policy/ 2023-12-11T16:15:17+00:00 https://blackfin.bio/terms-conditions-of-website-use/ 2023-12-11T16:20:01+00:00 https://blackfin.bio/privacy-policy/ 2023-12-12T19:10:17+00:00 https://blackfin.bio/contact-us/ 2025-01-06T15:24:25+00:00 https://blackfin.bio/wp-content/uploads/contact-pic-2.jpg https://blackfin.bio/wp-content/uploads/contact-pic-2.jpg https://blackfin.bio/acquisition-of-parkinsons-ip-patent-portfolio/ 2025-01-08T19:05:21+00:00 https://blackfin.bio/university-of-sheffield-spinout-company-blackfinbio-launches-to-pioneer-novel-therapies-for-genetic-neurological-diseasesnews-story/ 2025-01-08T19:05:38+00:00 https://blackfin.bio/investors/ 2025-02-21T18:20:33+00:00 https://blackfin.bio/wp-content/uploads/speak-marks.png https://blackfin.bio/wp-content/uploads/speak-marks-2.png https://blackfin.bio/about-us/ 2025-02-27T20:16:02+00:00 https://blackfin.bio/wp-content/uploads/mimoun-azzouz.jpg https://blackfin.bio/wp-content/uploads/mimoun-azzouz.jpg https://blackfin.bio/wp-content/uploads/peter-nolan.jpg https://blackfin.bio/wp-content/uploads/chris-edwards.png https://blackfin.bio/wp-content/uploads/darren-cunningham-1.jpg https://blackfin.bio/wp-content/uploads/kathleen-kirby-2.jpg https://blackfin.bio/blackfinbio-ltd-announces-submission-of-ind-application-to-the-u-s-fda-for-novel-aav-gene-therapy-to-treat-hereditary-spastic-paraplegia-type-47-spg47/ 2025-03-18T14:01:08+00:00 https://blackfin.bio/our-science/ 2025-04-25T10:48:17+00:00 https://blackfin.bio/wp-content/uploads/speak-marks.png https://blackfin.bio/wp-content/uploads/speak-marks-2.png https://blackfin.bio/newsroom/ 2025-04-28T06:44:22+00:00 https://blackfin.bio/blackfinbio-announces-fda-clearance-to-initiate-phase-1-2-clinical-trial-for-novel-aav-gene-therapy-bfb-101-to-treat-the-rare-neurological-disease-hereditary-spastic-paraplegia-type-47-spg47/ 2025-05-01T13:42:54+00:00 https://blackfin.bio/our-pipeline/ 2025-05-01T13:48:00+00:00 https://blackfin.bio/wp-content/uploads/pipeline.jpg